10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TSP50 Rabbit pAb

TSP50 Rabbit pAb
Catalog # AP58502

Product Information

Application	WB, IHC-P, IHC-F, IF
Primary Accession	Q9UI38
Predicted	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	43088
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human TSP50
Epitope Specificity	151-250/385
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SUBCELLULAR LOCATION	Endoplasmic reticulum (Probable). Note=May also localize to cytoplasmic membranes.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	TSP50 is a possible protease in human testes. It may function in mammalian spermatogenesis. Its linear catalytic structure is similar to many serine proteases, except for a Thr-for-Ser residual catalytic site substitution.

Additional Information

Gene ID	29122
Other Names	Probable threonine protease PRSS50, 3.4.25.-, Cancer/testis antigen 20, Serine protease 50, Testis-specific protease-like protein 50, PRSS50, CT20, TSP50
Dilution	WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	PRSS50
Synonyms	CT20, TSP50

Function	May be involved in proteolysis through its threonine endopeptidase activity.
Cellular Location	Endoplasmic reticulum. Note=May also localize to cytoplasmic membranes
Tissue Location	Testis specific. Differentially expressed in some breast cancer tissues

Background

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.